Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexbudesonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 13/20 | 1.00 |
| ▸ | PGR | P06401 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | IL5 | P05113 | 1/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | MMP9 | P14780 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Budesonide SCHEMBL16139563 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17168987 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL9763339 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL12440030 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL19635 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL10020756 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17151422 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17971368 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL13918824 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL21570019 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 84386 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6423298-B1 | — | — | None | — | — | US | claimed |
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122094727-A | Aerosol delivery device, component thereof and method of manufacturing the same | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137657-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| WO-2026102485-A1 | PRODUCTS AND METHODS FOR THE ASSESSMENT AND TREATMENT OF SEPSIS AND IMMUNOLOGICAL AND INFLAMMATORY CONDITIONS | CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC (AU) | 2026-05-21 | — | — | WO | claimed |
| US-20260137656-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| CN-122062959-A | Method for detecting particle size distribution of budesonide suspension preparation drug | 山东京卫制药有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-12633415-B2 | Pre-emptive asthma risk notifications based on medicament device monitoring | RESMED INC. (US) | 2026-05-19 | — | — | US | claimed |
| EP-0239798-A1 | New pharmaceutical compositions for inhalation | CHIESI FARMACEUTICI S.p.A. (IT) | 1987-10-07 | — | — | EP | claimed |
| US-4695625-A | Process for the preparation of 16,17 acetals of pregnane derivatives | SICOR SOCIETA ITALIANA CORTICOSTEROIDI S.P.A. (IT) | 1987-09-22 | — | — | US | claimed |
| WO-1987005213-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR INHALATION | CHIESI FARMACEUTICI S.P.A. (IT) | 1987-09-11 | — | — | WO | claimed |
| US-4606940-A | Small particle formation and encapsulation | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1986-08-19 | — | — | US | claimed |
| WO-1986003676-A1 | SMALL PARTICLE FORMATION AND ENCAPSULATION | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1986-07-03 | — | — | WO | claimed |
| EP-0170642-A2 | Liposomes containing steroid esters | Aktiebolaget Draco (SE) | 1986-02-05 | — | — | EP | claimed |
| EP-0164636-A2 | A process for the preparation of 16,17 acetals of pregnane derivatives and compounds obtained therefrom | SICOR Società Italiana Corticosteroidi S.p.A. (IT) | 1985-12-18 | — | — | EP | claimed |
| US-4524769-A | Dosage inhalator | AKTIEBOLAGET DRACO (SE) | 1985-06-25 | — | — | US | claimed |
| US-4427670-A | CONTAINING CORTICOSTEROID, PHOSPHATIDE, AND BUTYLHYDROXYANISOLE, OR BUTYLHYDROXYTOLUENE | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1984-01-24 | — | — | US | claimed |
| EP-0069715-A1 | Powder inhalator | Aktiebolaget Draco (SE) | 1983-01-12 | — | — | EP | claimed |